10-Q · May 15, 2026
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, significantly increasing from $8 million in Q1 2025. However, the company continues to experience a net loss of $60.6 million, widening from $33.9…
Earnings analysis · 10-Q
SPRY earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
ARS reported second-quarter revenue of $33.658 million, a substantial sequential and year-over-year rebound, but diluted EPS was negative $0.63 and the filing does not provide enough information to calculate current…
Read full summary
ARS reported second-quarter revenue of $33.658 million, a substantial sequential and year-over-year rebound, but diluted EPS was negative $0.63 and the filing does not provide enough information to calculate current gross or operating margin or free cash flow. Management highlighted second-half 2026 cash-based SG&A and R&D expenses of $100 million-$110 million and a path to cash-flow breakeven by the end of 2027. The outlook is offset by reliance on a single approved product, $100.0 million of debt subject to a $25.0 million minimum liquidity covenant, and newly disclosed litigation.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.63
What stood out
-
Revenue rebounded sharply
Second-quarter revenue was $33.658 million, up from $23 million in the immediately preceding quarter and $16 million in the prior-year quarter.
-
Expense reset targets breakeven
Management outlined second-half 2026 aggregate SG&A and R&D expense of $114 million-$126 million, including cash-based expenses of $100 million-$110 million, supporting a stated path to cash-flow breakeven by the end of 2027.
-
Reported liquidity runway
The company reported that existing cash and cash equivalents are expected to fund planned operations for at least three years, although management cautioned that the estimate could prove incorrect.
-
Broad patent position
ARS owns, co-owns or exclusively licenses eight issued U.S. patents directed to neffy and its uses, in addition to granted patents in multiple foreign jurisdictions.
What to watch
-
Single-product concentration
The filing adds a risk factor stating that the company is highly dependent on successful commercialization of neffy, its only approved product. Second-quarter revenue was $33.658 million, underscoring the concentration of the current commercial base.
-
Debt and liquidity covenant risk
As of June 30, 2026, outstanding Credit Agreement principal was $100.0 million, and the agreement requires at least $25.0 million of unrestricted cash and cash equivalents at all times. Failure to comply could permit lenders to accelerate repayment and pursue collateral.
-
New TCPA litigation
The filing adds disclosure of a putative TCPA class action filed on July 10, 2026, alleging unsolicited fax advertising for neffy; the complaint is Civil Action No. 3:26-cv-01339 and the outcome could materially affect operations and financial condition.
Management's outlook
No comparable prior outlook was disclosed. Management provided second-half 2026 aggregate SG&A and R&D expense guidance of $114 million-$126 million, including approximately $14 million-$16 million of stock-based compensation and $100 million-$110 million of cash-based expenses, and described a path to cash-flow breakeven by the end of 2027.
Earlier filings 4
10-K · March 9, 2026
ARS Pharmaceuticals reported a decline in total revenue for 2025, totaling $84.3 million, down 5% from 2024's revenue of $89.1 million, mainly due to a significant drop in revenue from collaboration agreements. The…
10-Q · November 10, 2025
ARS Pharmaceuticals reported Q3 2025 results showing significant revenue growth with total revenue of $32.5 million, up from $2.1 million in the same quarter of the previous year. Despite the revenue surprise, the…
10-Q · August 13, 2025
ARS Pharmaceuticals, Inc. reported a significant increase in revenue for Q2 2025, reaching $15.7 million, compared to just $0.5 million in the same quarter of the previous year, driven largely by the launch of its…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.